Combination Chemotherapy with 5-Fluorouracil and Heptaplatin as First-line Treatment in Patients with Advanced Gastric Cancer
Journal of Korean Medical Science
; : 369-373, 2004.
Article
en En
| WPRIM
| ID: wpr-124478
Biblioteca responsable:
WPRO
ABSTRACT
Heptaplatin is a recently developed platinum derivative. This agent has been reported to have a response rate of 17% as a single agent, and tolerable toxicity in the treatment of advanced gastric cancer. The aim of this study was to evaluate the efficacy and toxicity of a combination of 5-fluorouracil (5-FU) and heptaplatin in patients with advanced gastric cancer. Forty-seven chemotherapy-naive patients with advanced or recurred gastric cancer were recruited. 5-FU was administered over 120 hr by continuous intravenous infusion from day 1 to 5, at a daily dose of 1,000 mg/m2 and heptaplatin was administered over 1 hr by intravenous infusion on day 1 at 400 mg/m2, and this cycle was repeated every 4 weeks. The response rate was 21%, median progression-free survival was 1.9 months (95% CI, 1.6 to 2.2 months). Median overall survival was 6.2 months (95% CI, 4 to 8.4 months) and the 1-yr survival rate was 29% for all patients. The most frequent toxicity was proteinuria. Toxicities were generally mild and reversible. This study demonstrates that the combination of 5-FU/heptaplatin combination is less active but tolerated in patients with advance gastric cancer.
Palabras clave
Texto completo:
1
Base de datos:
WPRIM
Asunto principal:
Compuestos Organoplatinos
/
Neoplasias Gástricas
/
Factores de Tiempo
/
Protocolos de Quimioterapia Combinada Antineoplásica
/
Estudios de Seguimiento
/
Resultado del Tratamiento
/
Supervivencia sin Enfermedad
/
Fluorouracilo
/
Malonatos
Tipo de estudio:
Observational_studies
/
Prognostic_studies
Límite:
Adult
/
Aged
/
Female
/
Humans
/
Male
Idioma:
En
Revista:
Journal of Korean Medical Science
Año:
2004
Tipo del documento:
Article